1 / 8

Peptide Therapeutics Market Overview 2020

Peptide therapeutics market is expected to grow over the forecast period owing to the increasing prevalence of cancer and other various metabolic diseases

hexaresearchindustry
Download Presentation

Peptide Therapeutics Market Overview 2020

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Your Catalyst To a Lucrative Business Peptide Therapeutics Market Share, Size, Analysis, Growth, Trends and Forecasts to 2020 | Hexa Research "Peptide therapeutics market is expected to grow over the forecast period owing to the increasing prevalence of cancer and other various metabolic diseases." Rising cases of cancer and high incidence of a number of metabolic diseases propel the global Peptide Therapeutics Market. Other industry drivers are prevalence of lifestyle diseases, introduction of hybrid methods of peptides synthesis, growing global population, and improved healthcare infrastructure. A molecule containing two or more amino acids is known as a peptide. Therapeutic peptides are short amino acid monomer chains. Peptides are commonly known as amide bonds. These are used to treat blood-based disorders, certain types of cancers, chronic ailments, CNS (central nervous system) disorders, and cardiovascular & respiratory anomalies. Growing importance of peptide therapeutics in the pharmaceutical market may significantly contribute to overall demand during the forecast period (2012 to 2020). However, changing customer needs and lack of regulatory standards hinder industry progress. Browse Details of Report @ https://www.hexaresearch.com/research-report/peptide-therapeutics- industry Follow Us:

  2. Your Catalyst To a Lucrative Business The worldwide peptide therapeutics market is categorized on the basis of technologies, applications, routes of administration, products, and regions. Based on technologies, the segments are HPPS (hybrid phase peptide synthesis), LPPS (liquid phase peptide synthesis), and SPPS (solid phase peptide synthesis). Owing to cost effectiveness and user-friendliness, SPPS was the largest contributor to the overall industry in 2013.On the basis of applications, the market is divided into respiratory, cancer, anti-infection, pain, metabolic, cardiovascular, dermatology, renal, gastro intestinal, and others. In 2013, peptide therapeutics were used extensively in cancer treatment. High incidence of cancer cases worldwide is expected to fuel this segment till 2020. According to routes of administration, the industry is segmented into mucosal, pulmonary, parenteral, oral, and others. “Others” includes nasal and intradermal. Parenteral held the highest industry share in 2013. Based on products, the bifurcations are generic and innovative. Innovative peptides dominated the overall industry in 2013. As per regions, the global peptide therapeutics market is categorized into Europe, Asia Pacific, North America, and Rest of the World. North America leads the global industry because of high per capita expenditure on healthcare, rising income levels, and improvements in healthcare infrastructure. The region receives substantial support from the government and also from a number of NGOs. Asia Pacific may witness robust growth over the forecast period because of economic progress, favorable government initiatives, and growing population. Japan, China, and India are the three key regional drivers of the Asia Pacific market. Prominent companies operating in the global peptide therapeutics market are Eli Lilly and Company; Takeda Pharmaceutical Company Ltd.; Amylin Pharmaceuticals LLC; Bachem Holding AG; and Teva Pharmaceuticals. Rhythm, a U.S. based biopharmaceutical company dealing in peptide therapeutics presented the phase 2 clinical trial assessment of setmelanotide in November 2016. Setmelanotide, a peptide drug, is the company’s melanocortin-4 receptor agonist that is generally used to treat LepR (leptin receptor) deficiency obesity. This is a rare genetic anomaly that leads to unrelenting hyperphagia and severe obesity. According to the company, this disorder affects nearly two thousand people in the U.S. on an annual basis. Caused by deficiencies & defects in the MC4 pathway, LepR deficiency obesity affects people in their early childhood. The MC4 pathway in humans regulates appetite, energy expenditure, and homeostasis. Setmelanotide’s efficacy was tested by researchers when it was administered everyday by subcutaneous injection. Over a period of 22 weeks, a LepR patient lost weight by almost 20%. Browse Related Category Market Reports @ https://www.hexaresearch.com/research- category/healthcare-it-industry Follow Us:

  3. Your Catalyst To a Lucrative Business Table of Content of Peptide Therapeutics Market Chapter 1 Executive Summary 1.1 Peptide Therapeutics – Industry Summary & Critical Success Factors (CSFs) Chapter 2 Peptide Therapeutics Industry Outlook 2.1 Market Segmentation 2.2 Market Size and Growth Prospects 2.3 Peptide Therapeutics Value Chain Analysis 2.4 Peptide Therapeutics Market Dynamics 2.4.1 Market driver analysis 2.4.1.1 Increase in cancer patients 2.4.1.2 Increase in metabolic disorders 2.4.1.3 Growth in R&D 2.4.1.4 Technological advancement 2.4.2 Market restraint analysis 2.4.2.1 Increasing complexity 2.4.2.2 Lack of regulatory standards 2.4.2.3 Changing customer requirements 2.5 Key Opportunities Prioritized 2.6 Industry Analysis - Porter's 2.7 Peptide Therapeutics - Company Market Share Analysis 2.8 Peptide Therapeutics - PESTEL Analysis Chapter 3 Peptide TherapeuticsTechnologyOutlook 3.1 Solid Phase Peptide Synthesis (SPPS) 3.1.1. Global Peptide Therapeutics demand from SPPStechnology, 2012-2020 (USD Million) 3.2 Liquid Phase Peptide Synthesis (LPPS) 3.2.1 Global Peptide Therapeutics demand from LPPStechnology, 2012-2020 (USD Million) 3.3 Hybrid Phase Peptide Synthesis (HPSS) 3.3.1 Global Peptide Therapeutics demand from HPSStechnology, 2012-2020 (USD Million) Chapter 4 Peptide Therapeutics Application Outlook 4.1 Cancer 4.1.1 Peptide Therapeutic demand from cancer applications, 2012-2020 (USD Million) 4.2 Metabolic 4.2.1 Peptide Therapeutics demand from metabolicapplications, 2012-2020 (USD Million) 4.3 Cardiovascular 4.3.1 Peptide Therapeutics demand from cardiovascularapplications, 2012-2020 (USD Million) 4.4 Dermatology 4.4.1 Peptide Therapeutics demand from Dermatologyapplications, 2012-2020 (USD Million) 4.5 Anti-infection 4.5.1 Peptide Therapeutics demand from anti-infection applications, 2012-2020 (USD Million) 4.6 Gastro Intestinal 4.6.1 Peptide Therapeutics demand from gastro intestinal applications, 2012-2020 (USD Million) Follow Us:

  4. Your Catalyst To a Lucrative Business 4.7Renal 4.7.1 Peptide Therapeutics demand from renal applications, 2012-2020 (USD Million) 4.8 Respiratory 4.8.1 Peptide Therapeutics demand from respiratory applications, 2012-2020 (USD Million) 4.9 Pain 4.9.1 Peptide Therapeutics demand from pain applications, 2012-2020 (USD Million) 4.10 Others 4.10.1 Peptide Therapeutics demand from other applications, 2012-2020 (USD Million) Chapter 5 Peptide Therapeutics Route Outlook 5.1 Parenteral Route 5.1.1 Global Peptide Therapeutics demand from parenteral route, 2012-2020 (USD Million) 5.2 Oral Route 5.2.1 Global Peptide Therapeutics demand from oral route, 2012-2020 (USD Million) 5.3 Pulmonary Route 5.3.1 Global Peptide Therapeutics demand from pulmonary route, 2012-2020 (USD Million) 5.4 Mucosal Route 5.4.1 Global Peptide Therapeutics demand from mucosal route, 2012-2020 (USD Million) 5.5 Other Routes (Intradermal & Nasal) 5.5.1 Global Peptide Therapeutics demand from other routes, 2012-2020 (USD Million) Chapter 6 Peptide Therapeutics Product Outlook 6.1 Innovative 6.1.1 Global Peptide Therapeutics demand from innovative segment, 2012-2020 (USD Million) 6.2 Generic 6.2.1 Global Peptide Therapeutics demand from generic segment, 2012-2020 (USD Million) Chapter 7 Peptide Therapeutics Regional Outlook 7.1 North America 7.1.1 Peptide Therapeutics market volume & revenue by technology, 2012-2020 (USD Million) 7.1.2 Peptide Therapeutics market volume & revenue by application, 2012-2020 (USD Million) 7.1.3 Peptide Therapeutics market volume & revenue by route, 2012-2020 (USD Million) 7.1.4 Peptide Therapeutics market volume & revenue by product, 2012-2020 (USD Million) 7.2 Europe 7.2.1 Peptide Therapeutics market volume & revenue by technology, 2012-2020 (USD Million) 7.2.2 Peptide Therapeutics market volume & revenue by application, 2012-2020 (USD Million) 7.2.3 Peptide Therapeutics market volume & revenue by route, 2012-2020 (USD Million) 7.2.4 Peptide Therapeutics market volume & revenue by product, 2012-2020 (USD Million) 7.3 Asia Pacific 7.3.1 Peptide Therapeutics market volume & revenue by technology, 2012-2020 (USD Million) 7.3.2 Peptide Therapeutics market volume & revenue by application, 2012-2020 (USD Million) 7.3.3 Peptide Therapeutics market volume & revenue by route, 2012-2020 (USD Million) 7.3.4 Peptide Therapeutics market volume & revenue by product, 2012-2020 (USD Million) 7.4 RoW 7.4.1 Peptide Therapeutics market volume & revenue by technology, 2012- 2020 (USD Million) 7.4.2 Peptide Therapeutics market volume & revenue by application, 2012- 2020 (USD Million) Follow Us:

  5. Your Catalyst To a Lucrative Business 7.4.3 Peptide Therapeutics market volume & revenue by route, 2012- 2020 (USD Million) 7.4.4 Peptide Therapeutics market volume & revenue by product, 2012- 2020 (USD Million) Chapter 8 Competitive Landscape 8.1 Amgen Inc. 8.1.1 Company Overview 8.1.2 Financial Performance 8.1.3 Product Benchmarking 8.1.4 Strategic Initiatives 8.2 Amylin Pharmaceuticals LLC- Bristol- Myers Squibb (BMS) 8.2.1 Company Overview 8.2.2 Financial Performance 8.2.3 Product Benchmarking 8.2.4 Strategic Initiatives 8.3 AstraZeneca PLC 8.3.1 Company Overview 8.3.2 Financial Performance 8.3.3 Product Benchmarking 8.3.4 Strategic Initiatives 8.4 Bachem Holding AG 8.4.1 Company Overview 8.4.2 Financial Performance 8.4.3 Product Benchmarking 8.4.4 Strategic Initiatives 8.5 Eli Lilly and Company 8.5.1 Company Overview 8.5.2 Financial Performance 8.5.3 Product Benchmarking 8.5.4 Strategic Initiatives 8.6 GlaxoSmithKline (GSK) 8.6.1 Company Overview 8.6.2 Financial Performance 8.6.3 Product Benchmarking 8.6.4 Strategic Initiatives 8.7 Ipsen 8.7.1 Company Overview 8.7.2 Financial Performance 8.7.3 Product Benchmarking 8.7.4 Strategic Initiatives 8.8 Lonza Inc. 8.8.1 Company Overview 8.8.2 Financial Performance 8.8.3 Product Benchmarking 8.8.4 Strategic Initiatives 8.9 Merck & Co. 8.9.1 Company Overview Follow Us:

  6. Your Catalyst To a Lucrative Business 8.9.2 Financial Performance 8.9.3 Product Benchmarking 8.9.4 Strategic Initiatives 8.10 Novartis AG 8.10.1. Company Overview 8.10.2. Financial Performance 8.10.3. Product Benchmarking 8.10.4. Strategic Initiatives 8.11 Novo- Nordisk A/S 8.11.1. Company Overview 8.11.2. Financial Performance 8.11.3. Product Benchmarking 8.11.4. Strategic Initiatives 8.12 Peptisyntha 8.12.1. Company Overview 8.12.2. Financial Performance 8.12.3. Product Benchmarking 8.12.4. Strategic Initiatives 8.13 PolyPeptide Group. 8.13.1. Company Overview 8.13.2. Financial Performance 8.13.3. Product Benchmarking 8.13.4. Strategic Initiatives 8.14 Pfizer Inc. 8.14.1. Company Overview 8.14.2. Financial Performance 8.14.3. Product Benchmarking 8.14.4. Strategic Initiatives 8.15 Roche 8.15.1. Company Overview 8.15.2. Financial Performance 8.15.3. Product Benchmarking 8.15.4. Strategic Initiatives 8.16 Sanofi 8.16.1. Company Overview 8.16.2. Financial Performance 8.16.3. Product Benchmarking 8.16.4. Strategic Initiatives 8.17 Takeda Pharmaceutical Company Limited 8.17.1. Company Overview 8.17.2. Financial Performance 8.17.3. Product Benchmarking 8.17.4. Strategic Initiatives 8.18 Teva Pharmaceuticals 8.18.1. Company Overview 8.18.2. Financial Performance Follow Us:

  7. Your Catalyst To a Lucrative Business 8.18.3. Product Benchmarking 8.18.4. Strategic Initiatives Chapter 9 Methodology & Scope 9.1 Research Methodology 9.2 Research Scope & Assumptions 9.3 List of Data Sources Follow Us:

  8. Your Catalyst To a Lucrative Business About Us: Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives. Contact Us: Ryan Shaw Hexa Research Felton Office Plaza 6265 Highway 9 Felton, California 95018 United States Phone: +1-800-489-3075 Email: sales@hexaresearch.com Website - http://www.hexaresearch.com/ Follow Us:

More Related